Author Interviews, Cancer Research, Dermatology / 14.08.2019
Genetics Plays A Key Role in Where Moles Develop on Skin
MedicalResearch.com Interview with:
[caption id="attachment_50843" align="alignleft" width="160"]
Dr. Visconti[/caption]
Dr Alessia Visconti, PhD
Department of Twin Research
King's College London,
London
MedicalResearch.com: What is the background for this study?
Response: We know from previous studies that the body site where melanoma skin
cancer develops varies according to sex, with men having melanoma more
often on the head, neck, and trunk, and women on the legs.
The body site where moles, a major risk factor for melanoma development,
are more abundant also varies according to sex, at least in childhood,
with boys having more moles on the head, neck, and trunk, and girls on
the legs.
Dr. Visconti[/caption]
Dr Alessia Visconti, PhD
Department of Twin Research
King's College London,
London
MedicalResearch.com: What is the background for this study?
Response: We know from previous studies that the body site where melanoma skin
cancer develops varies according to sex, with men having melanoma more
often on the head, neck, and trunk, and women on the legs.
The body site where moles, a major risk factor for melanoma development,
are more abundant also varies according to sex, at least in childhood,
with boys having more moles on the head, neck, and trunk, and girls on
the legs.




Prof Ching-Chi Chi,[/caption]
Prof Ching-Chi Chi, MD, MMS, DPhil (Oxford)
Department of Dermatology
Chang Gung Memorial Hospital, Linkou
Taiwan
MedicalResearch.com: What is the background for this study?
Response: Psoriasis has been associated various inflammatory comorbidities including diabetes mellitus, coronary artery disease, etc. Moreover, obesity is prevalent among psoriasis patients and has been considered as an independent risk factor for occurrence and worsening of psoriasis by promoting systemic inflammation.
Notably, body weight (BW) gain of psoriasis patients after biologics use has been observed. However, there are inconsistent reports on whether biological therapy relates to BW gain.
Prof. Satchi-Fainaro[/caption]
Prof. Ronit Satchi-Fainaro, PhD
Head, Cancer Research and Nanomedicine Laboratory
Department of Physiology and Pharmacology,
Sackler Faculty of Medicine,
Tel Aviv University,
Tel-Aviv 69978, Israel
[caption id="attachment_50670" align="alignleft" width="116"]
Prof. Florindo[/caption]
Prof. Helena Florindo, PhD
Head, BioNanoSciences – iMed.ULisboa
Faculty of Pharmacy,
University of Lisbon
Lisbon, Portugal
MedicalResearch.com: What are the main findings?
Response: The war against cancer in general, and melanoma in particular, has advanced over the years through a variety of treatment modalities, such as surgery, chemotherapy, radiation therapy and immunotherapy. The immune checkpoint inhibitors brought a breakthrough solution for advanced melanoma patients, but only a low percentage of those respond to this therapy, developing resistance and being affected by severe side effects. Despite the success of several vaccines against viral diseases, this success has not been materialized yet against cancer.
This study led by my lab at Tel Aviv University, and Helena Florindo’s lab at the University of Lisbon, describes the development of an effective nano-vaccine against melanoma, that also sensitizes the immune system to immunotherapies.
This nano-vaccine prevented melanoma, and also led to remarkable tumor inhibition and prolonged survival in mice already affected by this disease.


Dr. Gery Guy[/caption]
Gery P. Guy Jr., PhD, MPH
Senior Health Economist
Division of Unintentional Injury Prevention
CDC
MedicalResearch.com: What is the background for this study?
Response: In 2017, among the 70,237 drug overdose deaths in the United States, 47,600 (67.8%) involved prescription or illicit opioids. Distribution of the opioid receptor antagonist naloxone to reverse overdose is a key part of the public health response to the opioid overdose epidemic. The 2016 CDC Guideline for Prescribing Opioids for Chronic Pain recommended clinicians consider offering naloxone when overdose risk factors, such as history of overdose or opioid use disorder, higher opioid dosages, or concurrent benzodiazepine use, are present.
However, recent analyses examining pharmacy-based naloxone dispensing are lacking. To address this gap and to inform future overdose prevention and response efforts, CDC examined trends and characteristics of naloxone dispensed from retail pharmacies at the national and county level in the United States.

